title: Ifosfamide nephrotoxicity in pediatric cancer patients.
abstract: The renal functions in pediatric cancer patients who received ifosfamide (IFO) treatment were evaluated and the risk factors related to IFO nephrotoxicity were determined. The medical records of all children treated with IFO were reviewed, and 62 with normal renal function before IFO treatment were selected. Nephrotoxicity was diagnosed by measuring urine beta2-microglobulin and glucose, and serum phosphate, bicarbonate, and creatinine. Forty-eight (77.4%) had a history of previous cisplatin treatment. Nephrotoxicity was detected in 20 patients (32.3%). beta2-Microglobulinuria was observed in all 20, hypophosphatemia in 10 (16.1%), hypocarbia in 2 (3.2%), glucosuria in 5 (8.1%), and decreased creatinine clearance in 7 (11.3%). The cumulative dose of IFO and a history of previous cisplatin therapy were related to nephrotoxicity. Among the 20 patients with nephrotoxicity, the median cumulative dose of IFO in patients with a low (<500 mg/m2) and high (>500 mg/m2) cumulative dose of previous cisplatin was 80 g/m2 (73-102 g/m2) and 45 g/m2 (11-76 g/m2), respectively. Most of the nephrotoxicity persisted after cessation of IFO treatment. In conclusion, close monitoring of IFO nephrotoxicity should be started earlier in patients with high-dose cisplatin pretreatment. Tubular proteinuria, as indicated by beta2-microglobulinuria, was the most-sensitive marker for IFO nephrotoxicity. Long-term follow-up study for reversibility of IFO nephrotoxicity is in progress.
authors.affiliation: Department of Pediatrics, Seoul National University Children's Hospital, Korea.
authors.forename: B S
authors.initials: BS
authors.lastname: Lee
authors.forename: J H
authors.initials: JH
authors.lastname: Lee
authors.forename: H G
authors.initials: HG
authors.lastname: Kang
authors.forename: H
authors.initials: H
authors.lastname: Hahn
authors.forename: J H
authors.initials: JH
authors.lastname: Lee
authors.forename: H Y
authors.initials: HY
authors.lastname: Shin
authors.forename: I S
authors.initials: IS
authors.lastname: Ha
authors.forename: H I
authors.initials: HI
authors.lastname: Cheong
authors.forename: H S
authors.initials: HS
authors.lastname: Ahn
authors.forename: Y
authors.initials: Y
authors.lastname: Choi
mesh_terms: D000293:Adolescent; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000009:adverse effects; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects* / Q000627:therapeutic use; D007223:Infant; D007674:Kidney Diseases / Q000139:chemically induced*; D008297:Male; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D018906:Antineoplastic Agents, Alkylating; D002945:Cisplatin; D007069:Ifosfamide